ERBB2 and adenocarcinoma: Overall, the existing findings collectively suggest that integrating immunotherapy with HER2-targeted therapy and chemotherapy is a promising approach for improving treatment outcomes in patients with HER2-positive G/GEJ adenocarcinoma.